Cookies Policy

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

I accept this policy

Find out more here

Therapeutic potential of bone marrow-derived endothelial progenitor cells for cardiovascular ischemic diseases

No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.

Brill’s MyBook program is exclusively available on BrillOnline Books and Journals. Students and scholars affiliated with an institution that has purchased a Brill E-Book on the BrillOnline platform automatically have access to the MyBook option for the title(s) acquired by the Library. Brill MyBook is a print-on-demand paperback copy which is sold at a favorably uniform low price.

This Article is currently unavailable for purchase.
Add to Favorites
You must be logged in to use this functionality

Post-natal vasculogenesis has been considered to be involved in neovascularization of adult tissues, after bone marrow-derived endothelial progenitor cells (EPCs) were isolated from circulating mononuclear cells in peripheral blood and shown to incorporate into sites of physiological and pathological neovascularization and differentiate into mature endothelial cells (ECs). Following these findings, the various strategies to enhance neovascularization using EPCs have been researched, such as in vivo mobilization through exogenous administration of angiogenic factors, ex vivo culture expansion for cell transplantation or gene therapy. EPCs might have an attractive potential in therapeutic application for cardiovascular ischemic diseases as a novel cell strategy.


Full text loading...


Data & Media loading...

Article metrics loading...



Can't access your account?
  • Key

  • Full access
  • Open Access
  • Partial/No accessInformation